Drug Trial Radar · NCT03907852
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
57
Actual
Start
Apr 15, 2019
Primary completion
Nov 19, 2024
Study completion Nov 2, 2028
Sponsor
- Lead sponsor
- TCR2 TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Apr 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.
Conditions
- Mesothelioma
- Mesothelioma, Malignant
- Mesothelioma; Pleura
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Cholangiocarcinoma
- Cholangiocarcinoma Recurrent
- Ovarian Cancer
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- High Grade Ovarian Serous Adenocarcinoma
Interventions
gavo-celBiological
gavo-cel
fludarabineDrug
lymphodepletion chemotherapy
cyclophosphamideDrug
lymphodepletion chemotherapy
NivolumabDrug
immuno-oncology agent
IpilimumabDrug
immuno-oncology agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1- Primary ObjectiveTime frame: DLTs within 28 days post-treatment
- Phase 2- Primary ObjectiveTime frame: ORR at 3 months; DCR based on ORR + SD lasting at least 8 weeks
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
University of Miami Sylvester Cancer Center
Miami, Florida
University of Chicago Medical Center
Chicago, Illinois
National Cancer Institute
Bethesda, Maryland
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University
Durham, North Carolina
University of Pennsylvania
Philadelphia, Pennsylvania
SCRI Oncology Partners
Nashville, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.